ASH 2024 – Piers Patten
Piers Patten discusses the potential of next-generation BCL-2 inhibitors like sonrotoclax compared to venetoclax in the treatment of CLL and shares insights on factors predictive of early MRD responses to BTK/BCL-2 inhibition in patients with CLL. He also provides an overview of the current understanding of the tumor microenvironment’s role in follicular lymphoma, highlighting key findings presented at ASH.
